Think Rheumatoid Arthritis: Causes, Consequences, and Management

This satellite symposium took place on 9th June 2016, as a part of the European League Against Rheumatism (EULAR) 17th annual congress in London, UK

Chairpersons: Josef Smolen,1 Costantino Pitzalis2
Speakers: Josef Smolen,1 Costantino Pitzalis,2 Simon Jones,3 Frank McKenna4

1. Medical University of Vienna and Hietzing Hospital, Vienna, Austria
2. Experimental Medicine and Rheumatology, Barts and the London School of Medicine and Dentistry, London, UK
3. Division of Infection and Immunity, The School of Medicine, Cardiff University, Cardiff, UK
4. University of Manchester, Manchester, UK

Disclosure: Professor Smolen has received grant support and/or honoraria from Abbvie, AstraZeneca, BMS, Celgene, Celtrion, GSK, ILTOO, Janssen, Lilly, MSD, Novartis-Sandoz, Pfizer, Roche, Samsung, and UCB. He is a co-editor of Rheumatology textbook (Elsevier), and a contributor to UpToDate. Professor Pitzalis has received consultant fees from various pharmaceutical and biotech companies; he has received honoraria and/or research/development grants from Abbott, AstraZeneca, MedImmune, Janssen (Johnson & Johnson), Pfizer, Sanofi, Roche, Genentech, Chugai, and UCB. Professor Jones has received grants/research support from Roche, NovImmune, and Ferring; he has also received honoraria or consultation fees from Roche, Chugai, NovImmune, Regeneron/Sanofi, Janssen (Johnson & Johnson), Eleven Biotherapeutics, Genentech, and UCB. Professor Jones has also participated in a speakers’ bureau sponsored by Roche and Chugai. Dr McKenna has received honoraria or consultant fees from Janssen and Sandoz, and has participated in a speakers’ bureau sponsored by Janssen.
Acknowledgements: Writing assistance was provided by Kabira Alieva of ApotheCom.
Support: The symposium was sponsored by Janssen Pharmaceutica NV. Authors received honoraria for preparation and delivery of their presentations. The views and opinions expressed are those of the authors and not necessarily of Janssen Pharmaceutica NV.
Citation: EMJ Rheumatol. 2016;3[1]:66–73.

Meeting Summary

Prof Josef Smolen opened the symposium and briefly described the aims of the meeting. Co-host Prof Constantino Pitzalis first discussed the pathophysiology of rheumatoid arthritis (RA), identifying the pro-inflammatory cytokines involved and explaining why specific drugs only work in certain conditions. Prof Simon Jones followed with a discussion on comorbidities and adverse events associated with interleukin (IL)-6 intervention in rheumatic disease. Dr Frank McKenna presented on the psychological impact of RA, including mood changes and development of depressive disorders, and Prof Smolen described the upcoming therapeutic approaches for the condition while also comparing and contrasting existing treatment options. The symposium concluded with a question and answer session.

Download (PDF, 337KB)

Comments are closed.